Piramal Pharma announced that US FDA has issued an Establishment Inspection Report (EIR) for the its manufacturing facility located at Lexington, USA and the inspection has now been successfully closed by the US FDA. Powered by Capital Market - Live News

Piramal Pharma announced that the Board of Directors of the Company at its meeting held on 10 May 2024, inter alia, have recommended the final dividend of Rs 0.11 per equity Share (i.e. 1.1%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Piramal Pharma rose 102.10% to Rs 101.27 crore in the quarter ended March 2024 as against Rs 50.11 crore during the previous quarter ended March 2023. Sales rose 17.97% to Rs 2552.36 crore in the quarter ended March 2024 as against Rs 2163.58 crore during the previous quarter ended March 2023.For the full year,net profit reported to Rs 17.82 crore in the year ended March 2024 as against net loss of Rs 186.46 crore during the previous year ended March 2023. Sales rose 15.39% to Rs 8171.16 crore in the year ended March 2024 as against Rs 7081.55 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales2552.362163.58 18 8171.167081.55 15 OPM %20.7616.24 -14.648.87 - PBDT454.13279.30 63 982.65563.50 74 PBT258.0094.89 172 242.08-113.19 LP NP101.2750.11 102 17.82-186.46 LP Powered by Capital Market - Live News

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 10 May 2024.Powered by Capital Market - Live News

Piramal Pharma announced its foray into men`s personal grooming category with the launch of BOHEM product range. This includes a Hair Removal Spray, a Beard Growth Oil, and an Underarm Roll-On. With BOHEM, Piramal Pharma intends to shift the grooming culture among men towards more inclusive self-care routines, leveraging scientifically proven ingredients for tangible results.Powered by Capital Market - Live News